Switching From Glargine+insulin Aspart to Glargine+insulin Aspart 30 Before Breakfast Combined With Exercise After Dinner and Dividing Meals for the Treatment of Type 2 Diabetes Patients With Poor Glucose Control – A Prospective Cohort Study

BMC Endocrine Disorders- United Kingdom

doi 10.1186/s12902-018-0297-4

Full Text

Abstract

Available in

Date

Authors

Publisher

Springer Science and Business Media LLC

Related search

Continuous Subcutaneous Insulin Infusion (CSII) of Insulin Aspart Versus Multiple Daily Injection of Insulin Aspart/Insulin Glargine in Type 1 Diabetic Patients Previously Treated With CSII

Diabetes Care
Internal MedicineEndocrinologyAdvancedMetabolismSpecialized NursingDiabetes
2005English

Safety, Immunogenicity and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People With Diabetes Also Using Insulin Glargine: 12-Month Results From the GEMELLI 1 Trial

Diabetes Technology and Therapeutics
MedicineEndocrinologyMedical Laboratory TechnologyMetabolismDiabetes
2020English

Efficacy and Safety of LY2963016 Insulin Glargine in Patients With Type 1 and Type 2 Diabetes Previously Treated With Insulin Glargine

Diabetes, Obesity and Metabolism
Internal MedicineEndocrinologyMetabolismDiabetes
2016English

15 Years of Experience With Biphasic Insulin Aspart 30 in Type 2 Diabetes

Drugs in R and D
Pharmacology
2018English

Comparison of a Soluble Co-Formulation of Insulin Degludec/Insulin Aspart vs Biphasic Insulin Aspart 30 in Type 2 Diabetes: A Randomised Trial

European Journal of Endocrinology
MedicineEndocrinologyMetabolismDiabetes
2012English

Use of Biphasic Insulin Aspart 30 in Type 2 Diabetes Treatment: Expert Panel Recommendations

Turkish Journal of Endocrinology and Metabolism
Internal MedicineEndocrinologyMetabolismDiabetes
2018English

Real World Outcomes of Adding Rapid-Acting Insulin Versus Switching to Analog Premix Insulin Among US Patients With Type 2 Diabetes Treated With Insulin Glargine

Patient Preference and Adherence
PharmacologyHealth PolicyMedicineToxicologySocial SciencesPharmaceutics
2013English

Safety and Effectiveness of Biphasic Insulin Aspart 30/70 (NovoMix®30) When Switching From Human Premix Insulin in Patients With Type 2 Diabetes: Subgroup Analysis From the 6-Month IMPROVE™ Observational Study

International Journal of Clinical Practice
Medicine
2009English

Improved Postprandial Glucose With Inhaled Technosphere Insulin Compared With Insulin Aspart in Patients With Type 1 Diabetes on Multiple Daily Injections: The STAT Study

Diabetes Technology and Therapeutics
MedicineEndocrinologyMedical Laboratory TechnologyMetabolismDiabetes
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy